Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6720002 | 0.90 | IDO1 (0.39) | IDO1APPKDM4EALDH1A1ABCB1 | |
| SCHEMBL6717128 | 0.89 | SLC6A4 (0.42) | IDO1APPALDH1A1ABCB1L3MBTL1 | |
| SCHEMBL6721585 | 0.89 | IDO1 (0.38) | IDO1APPKDM4EALDH1A1ABCB1 | |
| SCHEMBL6728445 | 0.85 | KDM4E (0.41) | IDO1KDM4EALDH1A1 | |
| SCHEMBL6721773 | 0.84 | IDO1 (0.43) | IDO1APPALDH1A1ABCB1L3MBTL1 | |
| SCHEMBL6717622 | 0.80 | IDO1 (0.39) | IDO1APPKDM4EALDH1A1ABCB1 | |
| SCHEMBL6719674 | 0.71 | L3MBTL1 (0.46) | IDO1APPKDM4EABCB1L3MBTL1 | |
| SCHEMBL1685765 | 0.71 | CA1 (0.48) | ALDH1A1L3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9344689 | 0.70 | CA1 (0.56) | ALDH1A1L3MBTL1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12936623 | 0.67 | IDO1 (0.60) | IDO1ALDH1A1ABCB1L3MBTL1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | IDO1 4197/4885APP 1385/4885KDM4E 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.